Soft-tissue sarcoma (STS) is a rare sarcoma that develops in connective tissues such as the muscles, nerves, tendons, blood vessels, and fatty and fibrous tissues.
As per DelveInsight Soft Tissue Sarcoma epidemiology analysis, STS incidence in the 7MM (the US, EU5 (the UK, Germany, France, Spain, and Italy) and Japan) in 2017 was 40,155.
Gain rich insights into the Soft tissue sarcoma, its signs, symptoms, causes, and treatment regimen. Know more about the disease overview, its epidemiological statistics, marketed therapies available, and unmet needs in the market through our newsletter.
Fill up a simple form and know more about the STS market landscape, ongoing clinical trials, and therapies in the pipeline that can transform the STS market in the next decade. Know about the major pharma companies in the market landscape, the recent collaborations and agreements, and the happenings at the research front advancing the STS market landscape.
Stay tuned for recent updates on Soft tissue sarcoma treatment landscape
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- Unmet needs
- Key Companies
- Market insights
- Clinical trials
- Pipeline drugs
- R&D in the field
- Support from International organizations